Multiplex Assay Kit for Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay)

CSF3; G-CSF; Granulocyte Colony Stimulating Factor; Pluripoietin; Filgrastim; Lenograstim

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 94-105 101
EDTA plasma(n=5) 85-94 90
heparin plasma(n=5) 88-101 94

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 87-94% 79-95% 81-93% 79-91%
EDTA plasma(n=5) 89-96% 96-103% 95-104% 98-105%
heparin plasma(n=5) 88-99% 87-101% 78-99% 86-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:GCSF) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Scientific Reports The Transcriptional Foundations of Sp110-mediated Macrophage (RAW264. 7) Resistance to Mycobacterium tuberculosis H37Ra Pubmed:26912204
International Journal of Clinical and Experimental Pathology Low-density neutrophils in severe fever with thrombocytopenia syndrome (SFTS) display decreased function to phagocytose SFTS virus and enhanced capacity to synthesize cytokines ISSN:1936-2625/IJCEP0045334
International Immunopharmacology Ginsenoside Rg3 improves cyclophosphamide-induced immunocompetence in Balb/c mice Pubmed: 30974284
Mol Immunol Oridonin alleviates kanamycin-related hearing loss by inhibiting NLRP3/caspase-1/gasdermin D-induced inflammasome activation and hair cell pyroptosis Pubmed:35749835
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
APA042Ra01 Active Colony Stimulating Factor 3, Granulocyte (GCSF) Cell culture; Activity Assays.
APA042Ra61 Active Colony Stimulating Factor 3, Granulocyte (GCSF) Cell culture; Activity Assays.
EPA042Ra61 Eukaryotic Colony Stimulating Factor 3, Granulocyte (GCSF) Positive Control; Immunogen; SDS-PAGE; WB.
RPA042Ra01 Recombinant Colony Stimulating Factor 3, Granulocyte (GCSF) Positive Control; Immunogen; SDS-PAGE; WB.
PAA042Ra01 Polyclonal Antibody to Colony Stimulating Factor 3, Granulocyte (GCSF) WB; IHC; ICC; IP.
MAA042Ra21 Monoclonal Antibody to Colony Stimulating Factor 3, Granulocyte (GCSF) WB; IHC; ICC; IP.
SEA042Ra ELISA Kit for Colony Stimulating Factor 3, Granulocyte (GCSF) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA042Ra CLIA Kit for Colony Stimulating Factor 3, Granulocyte (GCSF) Chemiluminescent immunoassay for Antigen Detection.
LMA042Ra Multiplex Assay Kit for Colony Stimulating Factor 3, Granulocyte (GCSF) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.